KALA BIO financials
$0.5033+11.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$1.7M | -$1.8M | -$10.2M | -$7.2M | -$11.0M | -$10.7M | -$9.5M | -$10.0M | -$9.6M | -$11.9M | -$9.6M | -$8.8M |
| Net income | -$1.6M | -$1.6M | $686.0K | -$7.6M | -$11.2M | -$8.9M | -$8.2M | -$8.9M | -$9.6M | -$11.8M | -$8.6M | -$8.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-21.32 | $-0.14 | $1.36 | $-53.50 | $-85.64 | $-70.49 | $-86.72 | $-96.50 | $-158.00 | $-210.00 | $-158.54 | $-170.50 |
| EBITDA | -$1.7M | -$1.8M | -$5.5M | -$10.5M | -$11.0M | -$10.6M | -$9.9M | -$9.5M | -$9.6M | -$11.7M | -$9.8M | -$8.7M |
| Operating cash flow | -$1.5M | -$2.9M | -$4.6M | -$10.9M | -$7.7M | -$8.8M | -$4.6M | -$4.7M | -$9.2M | -$10.8M | -$7.7M | -$3.0M |
| Free cash flow | -$1.5M | -$2.9M | -$4.6M | -$10.9M | -$7.7M | -$8.8M | -$4.7M | -$4.8M | -$9.3M | -$10.9M | -$7.7M | -$3.6M |
| Diluted shares | 0.1M | 11.9M | 0.5M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $229.0K | $1.8M | $7.6M | $21.1M | $31.9M | $42.2M |
| Short-term investments | $7.0M | $7.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $28.4M | $28.3M | $30.6M |
| Total assets | $10.6M | $12.3M | $9.5M | $25.0M | $36.1M | $48.3M |
| Total liabilities | $1.5M | $1.6M | $2.5M | $33.7M | $39.3M | $42.5M |
| Shareholders' equity | $9.0M | $10.8M | $7.0M | -$8.7M | -$3.2M | $5.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology